Repligen Co. (RGEN) Expected to Announce Earnings of $0.18 Per Share

Analysts predict that Repligen Co. (NASDAQ:RGEN) will post $0.18 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Repligen’s earnings. The lowest EPS estimate is $0.16 and the highest is $0.19. Repligen reported earnings per share of $0.15 in the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The business is expected to report its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Repligen will report full-year earnings of $0.71 per share for the current financial year, with EPS estimates ranging from $0.69 to $0.72. For the next fiscal year, analysts anticipate that the company will post earnings of $0.86 per share, with EPS estimates ranging from $0.82 to $0.90. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Repligen.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.02). The company had revenue of $47.73 million during the quarter, compared to analyst estimates of $45.84 million. Repligen had a net margin of 13.49% and a return on equity of 5.05%. The business’s revenue was up 47.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 EPS.

RGEN has been the topic of several recent analyst reports. HC Wainwright initiated coverage on Repligen in a research report on Wednesday. They set a “neutral” rating and a $49.00 target price on the stock. BidaskClub cut Repligen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. boosted their target price on Repligen to $60.00 and gave the stock an “overweight” rating in a research report on Monday. Zacks Investment Research cut Repligen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 7th. Finally, Citigroup boosted their target price on Repligen from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, July 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $49.38.

RGEN stock traded up $0.55 during trading on Friday, hitting $54.20. The company had a trading volume of 18,860 shares, compared to its average volume of 392,576. The stock has a market capitalization of $2.38 billion, a PE ratio of 78.14, a price-to-earnings-growth ratio of 4.38 and a beta of 0.72. Repligen has a 1-year low of $29.56 and a 1-year high of $58.99.

In other news, major shareholder Roy T. Eddleman sold 33,142 shares of the business’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $49.05, for a total transaction of $1,625,615.10. Following the sale, the insider now owns 413,985 shares of the company’s stock, valued at approximately $20,305,964.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anthony Hunt sold 27,566 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $57.71, for a total value of $1,590,833.86. Following the sale, the chief executive officer now directly owns 255,017 shares in the company, valued at approximately $14,717,031.07. The disclosure for this sale can be found here. Insiders have sold a total of 88,884 shares of company stock worth $4,693,683 in the last quarter. 1.40% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in RGEN. Rhumbline Advisers boosted its stake in shares of Repligen by 2.8% during the 1st quarter. Rhumbline Advisers now owns 105,594 shares of the biotechnology company’s stock worth $3,820,000 after acquiring an additional 2,860 shares in the last quarter. Mackay Shields LLC purchased a new stake in shares of Repligen during the 1st quarter worth approximately $749,000. Victory Capital Management Inc. boosted its stake in shares of Repligen by 38.9% during the 1st quarter. Victory Capital Management Inc. now owns 5,755 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 1,612 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Repligen by 2.3% during the 1st quarter. Prudential Financial Inc. now owns 63,565 shares of the biotechnology company’s stock worth $2,300,000 after acquiring an additional 1,450 shares in the last quarter. Finally, Aperio Group LLC boosted its stake in shares of Repligen by 7.6% during the 1st quarter. Aperio Group LLC now owns 35,583 shares of the biotechnology company’s stock worth $1,287,000 after acquiring an additional 2,520 shares in the last quarter. 92.50% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply